source
- Jasper Therapeutics merges with Kira Pharmaceuticals, divests Tavneos rival to MiradorJasper Therapeutics announced a merger with Nasdaq‑listed Kira Pharmaceuticals, positioning the combined company for a fresh strategic direction. The deal follows a difficult period for Jasper, whi…
- GSK halts camlipixant development after mixed Phase 3 results curb blockbuster hopesGSK announced it is stopping work on camlipixant, a P2X3 receptor antagonist it bought when acquiring Bellus Health in 2023, after the drug produced mixed results in two Phase 3 chronic cough trial…